Application of corymidine in preparation of medicine for treating rheumatoid arthritis

Through the in-depth development of cynomylamine and the combined use of other natural products, the problems of side effects of existing drugs and insufficient treatment choices have been solved, effective relief and inhibition of rheumatoid arthritis has been achieved, and new oral treatment has been provided Treatment plan.

CN118948846AActive Publication Date: 2024-11-15PEKING UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411299595.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-18
Publication Date
2024-11-15
Estimated Expiration
2044-09-18

AI Technical Summary

Technical Problem

Existing drugs for treating rheumatoid arthritis have side effects caused by high dose administration and lack of efficient, safe and inexpensive oral drugs of natural origin.

Method used

Modern pharmaceutical research methods are used to develop the natural product cynomylamine. Combined with pharmacodynamic experiments, it provides cynomylamine or its pharmaceutically acceptable salt for the treatment of rheumatoid arthritis, combined with other natural products such as Decarinine, forms oral medications to inhibit inflammation and joint damage.

Benefits of technology

Viagra midipine effectively relieves the symptoms of rheumatoid arthritis, reduces the number of immune cells, and inhibits synovial hyperplasia, provides a new treatment option, has significant synergistic effects, and reduces arthritis scores and joint damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948846A_ABST
    Figure CN118948846A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly relates to application of corymidine or pharmaceutically acceptable salt thereof in preparation of medicines for treating rheumatoid arthritis. Experimental results show that the corymidine can effectively relieve the foot swelling level of CIA rats, reduce the arthritis score and inhibit the progress of rheumatoid arthritis. Blood routine analysis shows that the quantity of immune cells in blood is reduced and the immune level of an organism is weakened by administration of the corymidine. In addition, experimental results also show that the corymidine can inhibit synovial hyperplasia and relieve joint injury. Therefore, the corymidine has the prospect of being developed into the oral medicine for treating the rheumatoid arthritis, more treatment choices are provided for clinically treating the rheumatoid arthritis, and the corymidine has important social benefits and economic values.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and specifically relates to the use of corydaline or a pharmaceutically acceptable salt thereof in preparing a medicine for treating rheumatoid arthritis. Background Art

[0002] Rheumatoid arthritis (RA) is a common inflammatory autoimmune disease. Epidemiology shows that the incidence of RA is 0.5% to 1%, and the incidence in women is about three times that in men. RA is characterized by persistent synovitis, systemic inflammation, and continuous production of autoantibodies. It is a chronic autoimmune disease with a protracted course of disease. Most patients will experience repeated symmetrical pain, swelling, and dysfunction in the small joints of the hands and feet, accompanied by morning stiffness. Its pathological features are mainly inflammatory cell infiltration and synovial cell hyperplasia, involving multiple joints throughout the body, affecting the patient's normal life, and severe cases will cause joint deformity and disability.

[0003] The treatment goal for RA patients is to control inflammation while preserving joint structure and function, preventing structural damage, and restoring normal human function to maximize the quality of life. At present, glucocorticoids, anti-inflammatory drugs, and disease-modifying antirheumatic drugs (DMARDs) are mainly used in clinical treatment of RA. In addition, in the context of precision medicine, biologics and targeted drugs will also be the future development direction for the treatment of RA. However, RA is a chronic disease that requires long-term medication to control the condition. Long-term high-dose administration can lead to gastrointestinal reactions and damage to the liver, kidneys, and blood system. Therefore, finding new drugs for the treatment of RA with higher efficacy and lower toxic side effects is still the future development direction for the prevention and treatment of RA.

[0004] Natural product monomer compounds are monomer components extracted and separated from natural products. They may have multiple pharmacological activities, such as antioxidant, anti-tumor, antibacterial, anti-inflammatory, etc. They have a single component and few side effects, and are valuable resources for new drug research and development. Corlumidin is an isoquinoline alkaloid. The compound is derived from traditional Chinese medicine such as Xia Tian Wu. The molecular formula of the compound is C 20 H 19 NO6, its chemical structure is as follows:

[0005]

[0006] Currently, there are relatively few studies on the pharmacological activity of corydaline, and there are no reports on the treatment of rheumatoid arthritis with corydaline. Summary of the invention

[0007] The purpose of the present invention is to solve the problem of insufficient oral drugs of natural origin for treating rheumatoid arthritis that are currently available for clinical use and are efficient, safe and inexpensive, to achieve in-depth development and utilization of natural products using modern drug research methods, and to provide the use of corydaline in the preparation of drugs for treating rheumatoid arthritis in combination with a large number of pharmacodynamic experimental studies.

[0008] Specifically, the present invention is realized through the following technical solutions:

[0009] The present invention provides the use of corydaline or a pharmaceutically acceptable salt thereof in preparing a medicine for treating rheumatoid arthritis.

[0010] Preferably, the pharmaceutically acceptable salt is selected from hydrochloride.

[0011] As an optional mode, in the above-mentioned use, the corydaline inhibits the progression of rheumatoid arthritis, reduces the number of immune cells in the blood, weakens the body's immune level, inhibits synovial hyperplasia, and relieves joint damage.

[0012] As an optional mode, in the above use, the medicine comprises a therapeutically effective amount of corydaline and a pharmaceutically acceptable carrier.

[0013] As an optional mode, in the above use, the medicine also comprises other natural products commonly used in clinical treatment of rheumatoid arthritis.

[0014] As an optional mode, in the above use, the active ingredients in the medicine are composed of corydaline and other natural products.

[0015] As an optional mode, in the above use, the other natural products are selected from one or more of the following: oridonin, triptolide, resveratrol, sclareol, curcumin, decarinine, borfenolin, punicalagin, gentisic acid or naringin.

[0016] Preferably, the other natural products are selected from decarinine.

[0017] As an optional mode, in the above-mentioned use, the weight ratio of the corydaline to the other natural products is 1:10 to 10:1.

[0018] As an optional manner, in the above-mentioned use, the weight ratio of the corydaline to the other natural products is 1:5 to 5:1.

[0019] Preferably, the weight ratio of the corydaline to the other natural products is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 or 1:10.

[0020] As an optional mode, in the above-mentioned use, when corydaline is used in combination with other natural products, the dosage forms of the former and the latter may be the same or different. Furthermore, the former and the latter may be administered simultaneously or separately.

[0021] As an optional mode, in the above use, the drug is in oral dosage form.

[0022] As an optional mode, in the above-mentioned use, the oral dosage form is selected from oral liquid, tablet, powder, capsule or granule.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] (1) The present invention combines my country's advantages in natural product research and discovers for the first time a new use of the natural product corydaline in the treatment of rheumatoid arthritis.

[0025] (2) The experimental results showed that corydaline can effectively alleviate the foot swelling level of CIA rats, reduce arthritis scores, and inhibit the progression of rheumatoid arthritis. Routine blood analysis showed that the administration of corydaline reduced the number of immune cells in the blood and weakened the body's immune level. In addition, the experimental results also showed that corydaline can inhibit synovial hyperplasia and relieve joint damage.

[0026] (3) Corydaline has the prospect of being developed into an oral drug for the treatment of rheumatoid arthritis, which provides more treatment options for the clinical treatment of rheumatoid arthritis and has important social benefits and economic value.

[0027] (4) In addition, the present invention also found that the combination of corydaline and certain natural products (especially decarinine) can produce significant synergistic effects in the treatment of rheumatoid arthritis. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0029] Figure 1: Changes in the volume of the hind paws of rats during the drug administration period. **, p < 0.01, compared with the CIA group.

[0030] Figure 2 : Changes in the thickness of the hind paws of rats during the drug administration period. **, p < 0.01, compared with the CIA group.

[0031] Figure 3 : Changes in arthritis scores of rats during the administration period. **, p < 0.01, compared with the CIA group.

[0032] Figure 4 : Micro-CT analysis of the ankle joints of rats after drug administration (bone injury evaluation).

[0033] Figure 5 : HE staining analysis of the ankle joints of rats after administration (evaluation of synovial hyperplasia).

[0034] Figure 6 : Safranin fast green staining analysis of the ankle joints of rats after administration (evaluation of cartilage destruction).

[0035] Figure 7 : S100A4 immunohistochemical analysis (analysis of synovial fibroblast marker) in the ankle joints of rats after administration.

[0036] Figure 8 : Immunohistochemical analysis of Vimentin (analysis of synovial fibroblast marker) in the ankle joints of rats after administration.

[0037] Fig. 9 : Corydaline inhibits the migration of synovial fibroblasts.

[0038] Fig.10 : Statistical graph of the inhibition of synovial fibroblast migration by corydaline. **, p<0.01, compared with the 0-dose group.

[0039] Fig.11 : MTT analysis of the inhibition of synovial fibroblast proliferation by corydaline. **, p < 0.01, compared with the 0-dose group.

[0040] Fig.12 :Edu staining analysis of the inhibition of synovial fibroblast proliferation by corydaline.

[0041] Fig.13 : Statistical analysis of edu staining of corydaline inhibiting the proliferation of synovial fibroblasts. *, p < 0.5; **, p < 0.01, compared with the 0-dose group. DETAILED DESCRIPTION

[0042] The inventors used modern drug research methods to deeply develop and utilize natural products, and through a large number of screenings, found for the first time that oral corydaline can effectively treat rheumatoid arthritis. On this basis, the present invention was completed.

[0043] The dosage form of the drug of the present invention is preferably an oral dosage form.

[0044] The oral dosage form is a capsule, tablet, granule or oral solution, preferably a tablet or capsule.

[0045] The pharmaceutically acceptable carrier refers to a conventional drug carrier in the field of pharmaceutical preparations, selected from one or more of fillers, binders, disintegrants, lubricants, suspending agents, wetting agents, pigments, flavoring agents, solvents, and surfactants.

[0046] The filler of the present invention includes but is not limited to starch, microcrystalline cellulose, sucrose, dextrin, lactose, powdered sugar, glucose, etc.; the lubricant includes but is not limited to magnesium stearate, stearic acid, sodium chloride, sodium oleate, sodium lauryl sulfate, poloxamer, etc.; the binder includes but is not limited to water, ethanol, starch slurry, syrup, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, sodium alginate, polyvinyl pyrrolidone, etc.; the disintegrant includes but is not limited to starch effervescent mixture, i.e. sodium bicarbonate and citric acid, tartaric acid, low-substituted hydroxypropyl cellulose, etc.; the suspending agent includes but is not limited to polysaccharides such as acacia gum, agar, alginic acid, cellulose ether and carboxymethyl chitosan, etc.; the solvent includes but is not limited to water, a balanced salt solution, etc.

[0047] The drug can be made into various solid oral preparations, liquid oral preparations, etc. Pharmaceutically acceptable oral solid preparations include: ordinary tablets, dispersible tablets, enteric-coated tablets, granules, capsules, dripping pills, powders, etc., and oral liquid preparations include oral liquids, emulsions, etc.

[0048] The above-mentioned various dosage forms can be prepared according to conventional processes in the field of pharmaceutical preparations.

[0049] "Corymidine" can be extracted and separated from plants such as summer holly containing the active ingredient by using conventional natural product extraction methods in the art, or it can be purchased from commercial products.

[0050] In the medical use described herein, the administration time, number of administrations and frequency of administration of corydaline need to be determined according to the specific diagnosis results of the disease, which is within the technical scope mastered by those skilled in the art.

[0051] The treatment plan for rats can be applied to humans, and the effective doses of all drugs for humans can be converted by the effective doses of the drugs for rats, which is also easy to achieve for ordinary technicians in this field.

[0052] In order to better understand the essence of the present invention, the pharmacodynamics experiment and its results are used in the following specific implementation part to further illustrate the new use of corydaline in the pharmaceutical field for treating rheumatoid arthritis.

[0053] The present invention will be further described with reference to specific embodiments below. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the scope of the present invention.

[0054] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0055] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.

[0056] In the following examples, for cost saving and other considerations, this application and another patent application for tetrahydrojatrorrhizine filed by the inventor on the same day share a normal control group, a model group, a positive drug control group and a group of natural product monomers for combined use.

[0057] Example 1: In vivo efficacy study of corydaline in a collagen-induced rheumatoid arthritis animal model

[0058] 1.1 Experimental methods:

[0059] Rheumatoid arthritis is an autoimmune disease characterized by synovitis, and its pathological manifestations include immune enhancement, synovial hyperplasia and destruction of bone tissue. The collagen-induced rat arthritis model (CIA model) can be used to simulate rheumatoid arthritis.

[0060] SD rats: 180-200 g, from the Department of Experimental Animal Science, Peking University Health Science Center, a total of 75, 8 weeks old, male, SPF grade, divided into 5 groups.

[0061] Animal groups: normal control group, 15 animals / group; CIA model group, 15 animals / group; positive drug group (methotrexate, 1 mg / kg / 2d), 15 animals / group; drug-treated group (corydalis alkaloids, 5 mg / kg / d, 20 mg / kg / d), divided into 2 groups, 15 animals / group in each.

[0062] Administration: intragastric administration.

[0063] Procedure: The animals were first divided into 7 groups according to the grouping scheme and were adaptively fed for 6 days to adapt to the environment. The animal room maintained a 12-hour light and 12-hour dark cycle. During this period, the animals were free to eat and drink. The experiment used bovine type II collagen injection at the base of the tail to establish the model. The specific method is as follows: (1) Bovine type II collagen solution: bovine type II collagen was dissolved in an acetic acid aqueous solution with a pH of 3 at a concentration of 2 mg / mL and mixed on a shaker at 4°C for 2 hours. (2) Emulsion I: 2 mg / mL bovine type II collagen solution was mixed with complete Freund's adjuvant in an equal volume of 1:1 and vortexed. (3) Emulsion II: 2 mg / mL bovine type II collagen solution was mixed with incomplete Freund's adjuvant in an equal volume of 1:1 and vortexed. After the SD rats were anesthetized with an anesthesia machine, 0.1 mL of emulsion I was subcutaneously injected at the base of the tail of the rats in the model group and the treatment group. After 7 days, the living status of the rats was observed. If there was no abnormality, the SD rats were anesthetized using an anesthesia machine. 0.1 mL of emulsion II was subcutaneously injected at the base of the tail of the rats in the model group and the treatment group. After 7 days, the model was successful (signs of successful establishment of the arthritis model: obvious swelling of the toes of the rat's hind legs, inability to bend the hind leg joints, and creeping walking), and grouping and drug administration began.

[0064] Animals in the drug group were given oral administration, while the control group and the model group were only given an equal volume of 0.5% CMC-Na solution. The level of foot swelling, paw thickness and arthritis score were monitored during the drug administration. Four weeks after drug administration, the animals were anesthetized, micro-CT scans were performed on the hind limbs, blood was collected from the orbits and euthanized.

[0065] Animal treatment and subsequent analysis: After anesthesia, blood was collected from the orbits, serum was separated, and the animals were euthanized to obtain spleen, thymus, hind limbs and other organs. Three animals were randomly selected from each group for paraffin embedding, and ankle joints were taken for HE staining, safranin fast green staining, and immunohistochemical analysis of S100A4 and vimentin.

[0066] Experimental data presentation method: Foot swelling level (foot volume), sole thickness and arthritis score are recorded in Figures 1 to 3 , each time point is the mean ± standard deviation of each group of data. Anticoagulation was detected by routine blood analyzer, and the results are reported in Table 1. The experimental data were statistically analyzed using GraphPad-Prism 6.0 software, using one-way analysis of variance (ANOVA) (test to compare the mean values ​​of each column to see if there is a significant difference, p < 0.05 is considered to be a significant difference.

[0067] 1.2 Experimental results:

[0068] The results showed that (see Figures 1 to 3), the foot volume, sole thickness and arthritis score of CIA rats were significantly higher than those of the normal group, and did not decrease during the administration period. Corydaline (CM) can effectively alleviate the foot swelling level of CIA rats, reduce the arthritis score, and inhibit the progression of rheumatoid arthritis.

[0069] Routine blood analysis showed that the administration of corydaline reduced the number of immune cells (neutrophils, lymphocytes) in the blood (see Table 1) and weakened the body's immune level.

[0070] Table 1: Results of blood routine analysis of various experimental animals after administration of corydaline

[0071]

[0072] CT analysis showed a reduction in bone damage (see Figure 4 ), HE staining showed that synovial proliferation was inhibited (see Figure 5 ), safranin fast green staining showed that it alleviated the cartilage destruction in CIA rats (see Figure 6 ), S100A4 and vimentin immunohistochemistry showed that the proliferation of synovial fibroblasts was inhibited (see Figures 7 and 8 ).

[0073] Example 2: In vitro effectiveness study of corydaline on primary synovial fibroblasts 2.1 Experimental methods:

[0074] The cells were obtained from primary synovial fibroblasts of rats with rheumatoid arthritis.

[0075] Primary rat synovial fibroblast culture: The synovial tissue of the rat hind foot joint was digested with 1 mg / mL type II collagenase at 37°C for 2 h, the supernatant was filtered with a filter, and the synovial fibroblasts were collected by centrifugation at 1000×g for 2 min. The cells were cultured in DMEM complete medium (DMEM high-glucose medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin mixed solution), and the culture conditions were 37°C, 5% CO2 and 95% humidity.

[0076] (1) MTT assay

[0077] Synovial fibroblasts were seeded in 48-well plates at a density of 2 × 10 4 / well, after growing in the incubator for 12 hours, the control group and the drug-treated group were randomly set up, and 4 wells were repeated. The control group was not treated, and the drug-treated group was treated with corydaline, and the concentration of corydaline was set to 1.5, 3 and 6 μM. After 24 hours of corydaline treatment, the original culture medium in the 48-well plate was carefully aspirated, and DMEM high-glucose medium containing 50 μg / mL MTT was added, and the reaction was protected from light for 4 hours under the culture conditions of 37°C, 5% CO2 and 95% humidity. Carefully aspirate the culture medium in the 48-well plate, add 350 μL DMSO to dissolve the purple crystals, and the sample absorbance is detected using a multifunctional microplate reader, and the detection wavelength is set to 570nm. Cell viability = (absorbance of the drug-treated group-blank) / (absorbance of the control group-blank)*100%.

[0078] (2) Wound healing experiment

[0079] Synovial fibroblasts were seeded in 12-well plates at a density of 5 × 10 5 / well, after the cells are fully grown, a sterile 200μL pipette tip is used to make a uniform wound. After washing with PBS twice, a control group and a treatment group were randomly set up. The control group was not treated, and the treatment group was treated with corydaline. The concentration of corydaline was set to 1.5, 3 and 6μM. After 24h of corydaline treatment, the culture medium in the 12-well plate was discarded, and the cells were fixed with 4% paraformaldehyde solution for 30min. Zeiss microscope was used to take images, and Image J software was used to analyze relative mobility. Relative mobility = (initial wound area-wound area after healing) / initial wound area*100%.

[0080] (3) Edu experiment

[0081] Synovial fibroblasts were seeded in 24-well plates at a density of 4 × 10 4 / well, after growing in the incubator for 12 hours, the control group and the drug-treated group were randomly set up, and repeated 3 wells. The control group was not treated, and the drug-treated group was treated with corydaline, and the concentration of corydaline was set to 1.5, 3 and 6 μM. After 4 hours of culture, the EdU solution with a final concentration of 10 μM preheated at 37°C was added. After incubation for 20 hours, the culture medium in the 24-well plate was carefully aspirated, and the cells were fixed with 4% paraformaldehyde solution at room temperature for 40 minutes. After washing the cells twice with PBS, 0.5% Triton X-100 PBS solution was used to punch holes at room temperature for 40 minutes. After washing the cells twice with PBS, 400 μL / well Click reaction solution (a mixed solution of 430 μL Click Reaction Buffer, 20 μL CuSO4, 1 μL AlexaFluor 488 and 50 μL Click Additive Solution) was added under light-proof conditions, and the reaction was carried out at room temperature in the dark for 30 minutes. The Click reaction solution was discarded, and the cells were washed three times with pre-cooled PBS. 400 μL of Hoechst33342 diluted with PBS at a ratio of 1:1000 was added to each well, and the cells were incubated at room temperature in the dark for 10 min. The cells were washed thoroughly with PBS, and images were taken with a Zeiss fluorescence microscope. Image J software was used to analyze the number of EDU-positive cells. The excitation / emission wavelengths of Alexa Fluor 488 were 495 nm / 520 nm, and the excitation / emission wavelengths of Hoechst33342 were 360 ​​nm / 450 nm. EDU-positive cell rate = number of 488-positive cells / number of cell nuclei * 100%. The experimental data were statistically analyzed using GraphPad-Prism 6.0 software. The method was to compare the mean values ​​of each column using the t-test under one-way analysis of variance (ANOVA) to see if there was a significant difference. p<0.05 was considered to be a significant difference.

[0082] 2.2 Experimental results:

[0083] Wound healing experiments showed that Figures 9 and 10 ), the wound healing degree of the drug-treated group was lower than that of the non-drug-treated group, indicating that CM inhibited the migration of synovial fibroblasts. MTT experiment (see Fig.11 ), edu proliferation assay (see Figure 12 to Figure 13 ), the number of edu-positive cells in the drug-treated group was significantly lower than that in the non-drug-treated group, indicating that CM inhibits the proliferation of synovial fibroblasts. CM can alleviate rheumatoid arthritis by inhibiting the proliferation of synovial fibroblasts.

[0084] Example 3: In vitro efficacy study of corydaline combined with other natural products on primary synovial fibroblasts

[0085] In this embodiment, the inventors also preliminarily investigated the effect of using corydaline in combination with a variety of other natural product monomers that may have the effect of treating rheumatoid arthritis (oridinol, triptolide, resveratrol, sclareol, curcumin, decarinine, pedunculaginine, punicalagin, gentisic acid, naringin).

[0086] 3.1 Experimental methods:

[0087] The cells were obtained from primary synovial fibroblasts of rats with rheumatoid arthritis.

[0088] Primary rat synovial fibroblast culture: The synovial tissue of the rat hind foot joint was digested with 1 mg / mL type II collagenase at 37°C for 2 h, the supernatant was filtered with a filter, and the synovial fibroblasts were collected by centrifugation at 1000×g for 2 min. The cells were cultured in DMEM complete medium (DMEM high-glucose medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin mixed solution), and the culture conditions were 37°C, 5% CO2 and 95% humidity.

[0089] MTT assay

[0090] Synovial fibroblasts were seeded in 48-well plates at a density of 2 × 10 4 / well, after growing in the incubator for 12 hours, the control group and the drug-treated group were randomly set up, and repeated for 4 wells. The control group was not treated, and the drug-treated group was treated with the above-mentioned various natural product monomers to be tested, and the concentration was set to 3μM. After 24 hours of drug treatment, the original culture medium in the 48-well plate was carefully aspirated, and DMEM high-glucose culture medium containing 50μg / mL MTT was added, and the reaction was protected from light for 4 hours under the conditions of 37°C, 5% CO2 and 95% humidity. Carefully aspirate the culture medium in the 48-well plate, add 350μL DMSO to dissolve the purple crystals, and the sample absorbance is detected using a multifunctional microplate reader, and the detection wavelength is set to 570nm. Cell viability = (absorbance of the drug-treated group-blank) / (absorbance of the control group-blank)*100%.

[0091] The experimental data were statistically analyzed using GraphPad-Prism 6.0 software. The method was to compare whether there was a significant difference in the mean value of each column using the t-test under one-way analysis of variance (ANOVA). A significant difference was considered when p < 0.05.

[0092] The synergy index is determined by the Kim Jong-gwan q value method, and the q value is calculated by the following formula:

[0093] q=P A+B / (P A +P B -P A ×P B). Where P A , P B and P A+B They are the treatment improvement rates of drug A group, drug B group and the combination of the two drugs. q<1 indicates that the two drugs produce an antagonistic effect after combination; q>1 indicates that the two drugs produce a synergistic effect after combination; q=1 indicates that the two drugs produce an additive effect after combination.

[0094] 3.2 Experimental results:

[0095] The experimental results are shown in Table 2 below.

[0096] Table 2 Survival rate of synovial fibroblasts in each drug group tested (%)

[0097]

[0098] The experimental results show that although natural product monomer compounds such as oridonin and triptolide may have different degrees of inhibitory effects on the proliferation of rat synovial fibroblasts when used alone, these natural product monomer compounds may have antagonistic effects, additive effects and synergistic effects when used in combination with corydaline. It can be seen that the effect of corydaline combined with other natural products on rat synovial fibroblasts is difficult to predict.

[0099] As shown in the results in Table 2, the combination of corydaline and decarinine may have a synergistic effect in the treatment of rheumatoid arthritis.

[0100] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. Use of corydaline or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating rheumatoid arthritis.

2. The use according to claim 1, characterized in that: The corydaline inhibits the progression of rheumatoid arthritis, reduces the number of immune cells in the blood, weakens the body's immune level, inhibits synovial hyperplasia, and relieves joint damage.

3. The use according to claim 1, characterized in that: The medicine comprises a therapeutically effective amount of corydaline and a pharmaceutically acceptable carrier.

4. The use according to claim 3, characterized in that: The medicine also contains other natural products commonly used in clinical treatment of rheumatoid arthritis.

5. The use according to claim 4, characterized in that: The active ingredients in the medicine are composed of corydaline and other natural products.

6. The use according to claim 5, characterized in that: The other natural products are selected from one or more of the following: oridonin, triptolide, resveratrol, sclareol, curcumin, decarinine, borfenolin, punicalagin, gentisic acid or naringin.

7. The use according to claim 6, characterized in that: The weight ratio of the corydaline to the other natural products is 1:10 to 10:

1.

8. The use according to claim 7, characterized in that: The weight ratio of the corydaline to the other natural products is 1:5 to 5:

1.

9. The use according to claim 1, characterized in that: The drug is in oral dosage form.

10. The use according to claim 9, characterized in that: The oral dosage form is selected from oral liquid, tablet, powder, capsule or granule.

Citation Information

Patent Citations

  • Bone joint disease recovery pharmaceutical composition and clinical application

    CN102451237A

  • Process technique to prepare rotundine based on different plants

    CN103145703A

  • Method for extracting protopine from decumbent corydalis tuber

    CN1683372A